NCT05075889View on ClinicalTrials.gov

Utility of ICG in Benign Bone Tumors

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

April 20, 2022

Study Completion Date

April 20, 2022

Conditions
Bone Tumor
Interventions
DRUG

Indocyanine Green

Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment

Trial Locations (1)

03766

Dartmouth-Hitchock, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT05075889 - Utility of ICG in Benign Bone Tumors | Biotech Hunter | Biotech Hunter